UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 20, 2009
VANDA PHARMACEUTICALS INC.
(Exact name of Registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
| |
|
|
000-51863
(Commission File No.)
|
|
03-0491827
(IRS Employer Identification No.) |
9605 Medical Center Drive
Suite 300
Rockville, Maryland 20850
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (240) 599-4500
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
|
|
|
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Vanda Pharmaceuticals Inc. (the “Company” or “Vanda”) made presentations regarding the
Company’s products, FanaptTM (iloperidone) and tasimelteon, to medical professionals,
analysts, investors and others at the Annual Meeting of the American Psychiatric Association (the
“APA Meeting”) on May 20, 2009. The posters that were be used for such presentations are furnished
as Exhibit 99.1 to this Form 8-K. In addition, the posters will be posted on the Company’s Web
site http://www.vandapharma.com.
Various statements to be made in the presentations, including statements in the posters
furnished as Exhibit 99.1 to this Form 8-K, are “forward-looking statements” under the securities
laws. Words such as, but not limited to, “believe,” “expect,” “anticipate,” “estimate,” “intend,”
“plan,” “targets,” “likely,” “will,” “would,” and “could,” and similar expressions or words,
identify forward-looking statements. Forward-looking statements are based upon current expectations
that involve risks, changes in circumstances, assumptions and uncertainties. Vanda is at an early
stage of development and may not ever have any products that generate significant revenue.
Important factors that could cause actual results to differ materially from those reflected in the
Company’s forward-looking statements include, among others: delays in the completion of Vanda’s
clinical trials; a failure of Vanda’s products to be demonstrably safe and effective; Vanda’s
failure to obtain regulatory approval for its products or to comply with ongoing regulatory
requirements for its products; a lack of acceptance of Vanda’s products in the marketplace, or a
failure to become or remain profitable; Vanda’s expectations regarding trends with respect to its
costs and expenses; Vanda’s inability to obtain the capital necessary to fund its commercial and
research and development activities; Vanda’s failure to identify or obtain rights to new products;
Vanda’s failure to develop or obtain sales, marketing and distribution resources and expertise or
to otherwise manage its growth; a loss of any of Vanda’s key scientists or management personnel;
losses incurred from product liability claims made against Vanda; a loss of rights to develop and
commercialize Vanda’s products under its license and sublicense agreements and other factors that
are described in the “Risk Factors” section (Part II, Item 1A) of Vanda’s quarterly report on Form
10-Q for the fiscal quarter ended March 31, 2009 (File No. 001-34186). In addition to the risks
described above and in Part II, Item 1A of Vanda’s quarterly report on Form 10-Q, other unknown or
unpredictable factors also could affect Vanda’s results. There can be no assurance that the actual
results or developments anticipated by Vanda will be realized or, even if substantially realized,
that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can
be given that the outcomes stated in such forward-looking statements and estimates will be
achieved.
All written and verbal forward-looking statements attributable to Vanda or any person acting
on its behalf are expressly qualified in their entirety by the cautionary statements contained or
referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking
statements Vanda makes or that are made on its behalf. The information in this release is provided
only as of the date of this release, and Vanda undertakes no obligation, and specifically declines
any obligation, to update or revise publicly any forward-looking statements, whether as a result of
new information, future events or otherwise.
The information in the posters attached as Exhibit 99.1 to this Form 8-K will be provided only
as of the date on which such posters are presented, and the Company undertakes no obligation to
update any forward-looking statements contained in such posters from and after the date of such
presentations whether as a result of new information, future events or otherwise.
The information in Item 8.01 of this Form 8-K and the posters attached as Exhibit 99.1 to this
Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of
1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference in such a filing.